Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults
Co-authored by Debora Manning, MPH, a Strategic Consulting Fellow and Biostatistician at Veristat, this research article presents the findings of a Phase 1 randomized, double-blind study targeting the acute treatment of migraines. The study evaluated the safety, tolerability, and systemic pharmacokinetics (PK) of a dry powder formulation of DHE when administered via inhalation versus intravenous delivery. For more insights, read the full article now.
downloadExplore Our Key Related Services
Please fill out this form to access your resource.